曾接受鲁索替尼治疗的急变期骨髓增殖性肿瘤：突变与生存情况的对比分析 - Suppr

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.

作者信息

Abdelmagid Maymona G, Al-Kali Aref, Begna Kebede H, Hogan William J, Litzow Mark R, Fleti Farah, Mangaonkar Abhishek A, Patnaik Mrinal S, Elliott Michelle A, Alkhateeb Hassan, Shi Min, Howard Matthew T, Reichard Kaaren K, Ketterling Rhett P, Shah Mithun, Pardanani Animesh, Gangat Naseema, Tefferi Ayalew

机构信息

Divisions of Hematology and Medicine.

Divisions of Hematopathology, Departments of Laboratory Medicine, Mayo Clinic, Rochester, MN.

出版信息

Haematologica. 2023 Sep 1;108(9):2542-2545. doi: 10.3324/haematol.2022.282627.

DOI:10.3324/haematol.2022.282627

PMID:36794509

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10483339/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/10483339/aa413ff1f5dc/1082542.fig1.jpg

相似文献

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.

Haematologica. 2023 Sep 1;108(9):2542-2545. doi: 10.3324/haematol.2022.282627.

Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.

Br J Haematol. 2014 Dec;167(5):714-6. doi: 10.1111/bjh.13046. Epub 2014 Jul 22.

Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.

Leuk Res. 2012 Mar;36(3):377-81. doi: 10.1016/j.leukres.2011.10.009. Epub 2011 Oct 24.

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.

Am J Hematol. 2021 Jul 1;96(7):781-789. doi: 10.1002/ajh.26186. Epub 2021 May 6.

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.

Br J Haematol. 2023 Jul;202(2):284-288. doi: 10.1111/bjh.18853. Epub 2023 May 14.

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.

Leukemia. 2010 Oct;24(10):1713-8. doi: 10.1038/leu.2010.163. Epub 2010 Aug 19.

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.

Blood Cancer J. 2023 Feb 17;13(1):26. doi: 10.1038/s41408-023-00800-2.

Accelerated Phase of Myeloproliferative Neoplasms.

Acta Haematol. 2021;144(5):484-499. doi: 10.1159/000512929. Epub 2021 Apr 21.

Accelerated and Blast Phase Myeloproliferative Neoplasms.

Hematol Oncol Clin North Am. 2021 Apr;35(2):325-335. doi: 10.1016/j.hoc.2020.12.008. Epub 2021 Feb 3.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

引用本文的文献

How I treat secondary acute myeloid leukemia.

Blood. 2025 Mar 20;145(12):1260-1272. doi: 10.1182/blood.2024024011.

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.

Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8.

本文引用的文献

The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms.

Am J Hematol. 2023 Mar;98(3):544-545. doi: 10.1002/ajh.26821. Epub 2023 Jan 4.

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.

Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.

Cancer Res. 2022 Mar 1;82(5):749-763. doi: 10.1158/0008-5472.CAN-21-2930.

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.

Am J Hematol. 2021 Jul 1;96(7):781-789. doi: 10.1002/ajh.26186. Epub 2021 May 6.

Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.

Br J Haematol. 2021 May;193(4):792-797. doi: 10.1111/bjh.17375. Epub 2021 Mar 9.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.

Blood. 2018 Nov 29;132(22):2339-2350. doi: 10.1182/blood-2018-03-785907. Epub 2018 Oct 17.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.

作者信息

机构信息

Divisions of Hematology and Medicine.

Divisions of Hematopathology, Departments of Laboratory Medicine, Mayo Clinic, Rochester, MN.

出版信息

Haematologica. 2023 Sep 1;108(9):2542-2545. doi: 10.3324/haematol.2022.282627.

DOI:10.3324/haematol.2022.282627

PMID:36794509

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10483339/

Abstract

摘要

相似文献

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.

Haematologica. 2023 Sep 1;108(9):2542-2545. doi: 10.3324/haematol.2022.282627.

Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.

Br J Haematol. 2014 Dec;167(5):714-6. doi: 10.1111/bjh.13046. Epub 2014 Jul 22.

Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.

Leuk Res. 2012 Mar;36(3):377-81. doi: 10.1016/j.leukres.2011.10.009. Epub 2011 Oct 24.

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.

Am J Hematol. 2021 Jul 1;96(7):781-789. doi: 10.1002/ajh.26186. Epub 2021 May 6.

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.

Br J Haematol. 2023 Jul;202(2):284-288. doi: 10.1111/bjh.18853. Epub 2023 May 14.

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.

Leukemia. 2010 Oct;24(10):1713-8. doi: 10.1038/leu.2010.163. Epub 2010 Aug 19.

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.

Blood Cancer J. 2023 Feb 17;13(1):26. doi: 10.1038/s41408-023-00800-2.

Accelerated Phase of Myeloproliferative Neoplasms.

Acta Haematol. 2021;144(5):484-499. doi: 10.1159/000512929. Epub 2021 Apr 21.

Accelerated and Blast Phase Myeloproliferative Neoplasms.

Hematol Oncol Clin North Am. 2021 Apr;35(2):325-335. doi: 10.1016/j.hoc.2020.12.008. Epub 2021 Feb 3.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

引用本文的文献

How I treat secondary acute myeloid leukemia.

Blood. 2025 Mar 20;145(12):1260-1272. doi: 10.1182/blood.2024024011.

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.

Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8.

本文引用的文献

The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms.

Am J Hematol. 2023 Mar;98(3):544-545. doi: 10.1002/ajh.26821. Epub 2023 Jan 4.

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.

Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.

Cancer Res. 2022 Mar 1;82(5):749-763. doi: 10.1158/0008-5472.CAN-21-2930.

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.

Am J Hematol. 2021 Jul 1;96(7):781-789. doi: 10.1002/ajh.26186. Epub 2021 May 6.

Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.

Br J Haematol. 2021 May;193(4):792-797. doi: 10.1111/bjh.17375. Epub 2021 Mar 9.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.

Blood. 2018 Nov 29;132(22):2339-2350. doi: 10.1182/blood-2018-03-785907. Epub 2018 Oct 17.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献